Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/22/2023* -- Results Q4 2022 -- -0.45 --
03/22/2023* 16:30 EST Earnings Call Q4 2022 -- -- --
11/08/2022 -- Results Q3 2022 -0.39 -0.48 18.23%
11/08/2022 16:30 EST Earnings Call Q3 2022 -- -- --
08/09/2022 -- Results Q2 2022 -0.50 -0.51 1.32%
08/09/2022 16:30 EST Earnings Call Q2 2022 -- -- --
05/10/2022 -- Results Q1 2022 -0.45 -0.50 10.00%
05/10/2022 16:30 EST Earnings Call Q1 2022 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 03/22/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/08/2022
Beat/Miss Upgrade
Return Since -16.17%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Codex DNA Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide.
URL https://www.codexdna.com
Investor Relations URL https://ir.codexdna.com/
HQ State/Province California
Sector Healthcare
Industry Medical Devices
Equity Style N/A
Next Earnings Release Mar. 22, 2023 (est.)
Last Earnings Release Nov. 08, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
--
--
--
--
-87.04%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-15.74%
--
--
--
--
--
--
-17.38%
-44.57%
--
--
--
--
--
--
-88.62%
-89.51%
--
--
--
--
--
--
--
-50.00%
--
--
--
--
--
--
--
-84.03%
As of November 29, 2022.

Profile

Edit
Codex DNA Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide.
URL https://www.codexdna.com
Investor Relations URL https://ir.codexdna.com/
HQ State/Province California
Sector Healthcare
Industry Medical Devices
Equity Style N/A
Next Earnings Release Mar. 22, 2023 (est.)
Last Earnings Release Nov. 08, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter DNAY Tweets